{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:57:31Z","timestamp":1790582251767,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00834-9","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:31:30Z","timestamp":1790580690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-generation CAR-T therapy for malignant brain tumors: latest updates from the 2026 AACR Annual Meeting"],"prefix":"10.1186","volume":"15","author":[{"given":"Valbert Oliveira","family":"Costa Filho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Helena Barem","family":"Rabenhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Pantoja","family":"Mesquita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"834_CR1","doi-asserted-by":"publisher","first-page":"CT042","DOI":"10.1158\/1538-7445.am2026-ct042","volume":"86","author":"PB Watchmaker","year":"2026","unstructured":"Watchmaker PB, Clarke JL, Almeida R, Yamamichi A, Hansen A, Gopi HT, et al. Abstract CT042: First-in-human trial of E-SYNC T-cells, an autologous anti-EGFRvIII SynNotch receptor-induced anti-EphA2\/IL13Ra2 CAR T-cells, in adult patients with EGFRvIII+ glioblastoma. Cancer Res. 2026;86:CT042\u2013042. https:\/\/doi.org\/10.1158\/1538-7445.am2026-ct042","journal-title":"Cancer Res"},{"key":"834_CR2","doi-asserted-by":"publisher","first-page":"CT070","DOI":"10.1158\/1538-7445.am2026-ct070","volume":"86","author":"MP Le Brown","year":"2026","unstructured":"Brown MP, Le Blanc A, Khan S, Patel S, Logan J, Franze O, et al. Abstract CT070: Initial clinical and laboratory results of an ongoing dose escalation study of autologous GD2-CAR-T cells in patients with recurrent GD2-positive glioblastoma. Cancer Res. 2026;86:CT070\u2013070. https:\/\/doi.org\/10.1158\/1538-7445.am2026-ct070","journal-title":"Cancer Res"},{"key":"834_CR3","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1158\/1538-7445.am2026-3444","volume":"86","author":"WV Wilson","year":"2026","unstructured":"Wilson WV, Nasrallah MP, Cross N, Day YA, Gonzalez V, Leskowitz RM, et al. Abstract 3444: Spatial profiling of recurrent glioblastoma in a Phase I clinical trial reveals favorable immune remodeling induced by intracerebroventricular CAR T therapy. Cancer Res. 2026;86:3444\u20133444. https:\/\/doi.org\/10.1158\/1538-7445.am2026-3444","journal-title":"Cancer Res"},{"key":"834_CR4","doi-asserted-by":"publisher","first-page":"6463","DOI":"10.1158\/1538-7445.am2026-6463","volume":"86","author":"Y Chen","year":"2026","unstructured":"Chen Y, Song K-W, Desai MH, Huang Y-W, Iswari N, Ehlinger ZJ, et al. Abstract 6463: Longitudinal single-cell atlas of GD2-CAR T cell therapy in H3K27M-mutant diffuse midline glioma identifies humoral and cellular anti-CAR immunity. Cancer Res. 2026;86:6463\u20136463. https:\/\/doi.org\/10.1158\/1538-7445.am2026-6463","journal-title":"Cancer Res"},{"key":"834_CR5","doi-asserted-by":"publisher","first-page":"LB138","DOI":"10.1158\/1538-7445.am2026-lb138","volume":"86","author":"J Xu","year":"2026","unstructured":"Xu J, Thokala R, Yin Y, Xu C, Boesteanu AC, Cogdill AP, et al. Abstract LB138: Natural killer cell-based signaling in EGFR-targeted KIR-CAR T overcomes CD3-based CAR T functional deficits to eliminate resistant glioblastomas in vivo. Cancer Res. 2026;86:LB138\u2013138. https:\/\/doi.org\/10.1158\/1538-7445.am2026-lb138","journal-title":"Cancer Res"},{"key":"834_CR6","doi-asserted-by":"publisher","first-page":"LB143","DOI":"10.1158\/1538-7445.am2026-lb143","volume":"86","author":"D Lee","year":"2026","unstructured":"Lee D, Kim Y-S, Vedvyas Y, Fredette N, Jin M, Min I. Abstract LB143: Modulation of G3BP1 influences the functional efficacy of CAR T cells against glioblastoma. Cancer Res. 2026;86:LB143\u2013143. https:\/\/doi.org\/10.1158\/1538-7445.am2026-lb143","journal-title":"Cancer Res"},{"key":"834_CR7","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1158\/1538-7445.am2026-1339","volume":"86","author":"K Watanabe","year":"2026","unstructured":"Watanabe K, Yamaguchi J, Nakamura A, Lin Y-T, Itahashi K, Koyama S, et al. Abstract 1339: On-demand GLUT3 expression augments CAR-T cell metabolic fitness and antitumor efficacy while preventing toxicity in glioblastoma models. Cancer Res. 2026;86:1339\u20131339. https:\/\/doi.org\/10.1158\/1538-7445.am2026-1339","journal-title":"Cancer Res"},{"key":"834_CR8","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1158\/1538-7445.am2026-3708","volume":"86","author":"D Gumber","year":"2026","unstructured":"Gumber D, Priceman S, Brown CE, Wang LD. Abstract 3708: Improving antitumor T cell therapy with membrane-tethered engineered cytokine agonists. Cancer Res. 2026;86:3708\u20133708. https:\/\/doi.org\/10.1158\/1538-7445.am2026-3708","journal-title":"Cancer Res"},{"key":"834_CR9","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1158\/1538-7445.am2026-1528","volume":"86","author":"M Suarez","year":"2026","unstructured":"Suarez M, Abdallah A, Zhai X, Huang Z, Du Y, Wadhwani N, et al. Abstract 1528: AZD5851, a TGF-\u03b2-resistant GPC3 CAR-T cell product, prolongs animal survival times in patient derived orthotopic xenograft models of medulloblastoma and atypical teratoid rhabdoid tumor. Cancer Res. 2026;86:1528\u20131528. https:\/\/doi.org\/10.1158\/1538-7445.am2026-1528","journal-title":"Cancer Res"},{"key":"834_CR10","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1158\/1538-7445.am2026-4009","volume":"86","author":"D Usta","year":"2026","unstructured":"Usta D, Gwynne W, Suk Y, Chen Y, Radosevich MT, Chernova D, et al. Abstract 4009: Decoding the medulloblastoma surfaceome prioritizes the oncofetal antigen GPC2 for potent CAR-T cell therapy. Cancer Res. 2026;86:4009\u20134009. https:\/\/doi.org\/10.1158\/1538-7445.am2026-4009","journal-title":"Cancer Res"},{"key":"834_CR11","doi-asserted-by":"publisher","unstructured":"Singh SK, Savage N, Shaikh MV, Grewal S, Zemp FJ, Mikolajewicz N et al. Abstract 4044: GPNMB CAR-T cells target both glioblastoma and the tumor microenvironment to relieve immune suppression. Cancer Res. 2026;86:4044\u20134044. https:\/\/doi.org\/10.1158\/1538-7445.am2026-4044","DOI":"10.1158\/1538-7445.am2026-4044"},{"key":"834_CR12","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1158\/1538-7445.am2026-5191","volume":"86","author":"AA Mohan","year":"2026","unstructured":"Mohan AA, Lipes B, Yerrabelli R, Patel KK, Gentry C, Gonzalez A, et al. Abstract 5191: Multiscale engineering of PTPRZ1 CAR T cells through affinity-tuned binders and modular architecture optimization. Cancer Res. 2026;86:5191\u20135191. https:\/\/doi.org\/10.1158\/1538-7445.am2026-5191","journal-title":"Cancer Res"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00834-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00834-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00834-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:31:31Z","timestamp":1790580691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00834-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["834"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00834-9","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"3 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"101"}}